Research Analysts Offer Predictions for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for shares of Arcus Biosciences in a research note issued to investors on Tuesday, March 11th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($3.65) for the year, up from their prior forecast of ($5.29). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share.

RCUS has been the subject of several other research reports. HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their price target for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Finally, Bank of America reduced their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $30.25.

Arcus Biosciences Stock Down 2.0 %

Shares of NYSE:RCUS traded down $0.19 during trading hours on Thursday, hitting $9.15. The company's stock had a trading volume of 1,016,238 shares, compared to its average volume of 715,753. Arcus Biosciences has a 52 week low of $8.98 and a 52 week high of $19.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company has a market capitalization of $962.43 million, a price-to-earnings ratio of -2.91 and a beta of 1.36. The firm's fifty day moving average price is $12.25 and its 200 day moving average price is $14.87.

Remove Ads

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million.

Insiders Place Their Bets

In related news, CEO Terry J. Rosen bought 19,800 shares of the company's stock in a transaction on Thursday, February 27th. The shares were bought at an average price of $10.18 per share, with a total value of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert C. Goeltz II sold 3,594 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at approximately $902,070. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. 12.30% of the stock is owned by insiders.

Institutional Trading of Arcus Biosciences

Several large investors have recently made changes to their positions in RCUS. Quest Partners LLC boosted its holdings in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company's stock valued at $144,000 after acquiring an additional 9,408 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Arcus Biosciences by 25.1% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company's stock valued at $14,236,000 after acquiring an additional 186,750 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Arcus Biosciences during the third quarter worth $244,000. Massachusetts Financial Services Co. MA boosted its holdings in Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company's stock worth $1,237,000 after buying an additional 22,716 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Arcus Biosciences by 11.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock worth $8,669,000 after buying an additional 59,536 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.